Increased CD36 expression signals monocyte activation among patients with type 2 diabetes

Yijuan Sun, Marina Scavini, Robert A. Orlando, Glen H. Murata, Karen S. Servilla, Antonios H. Tzamaloukas, Ronald Schrader, Edward J. Bedrick, Mark R. Burge, Nada A. Abumrad, Philip G. Zager

Research output: Contribution to journalArticlepeer-review


OBJECTIVE - To explore the hypothesis that CD36, a scavenger receptor and fatty acid translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with type 2 diabetes and is a biomarker of PBMC activation and inflammation. RESEARCH DESIGN AND METHODS - We used a cross-sectional observational design to study a multi-racial/ethnic population sample consisting of Caucasians, Hispanics, and Native Americans with type 2 diabetes (n = 33) and nondiabetic control subjects (n = 27). PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs-interleukin-6 (hsIL-6), and adiponectin were measured. RESULTS - Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher, respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with plasma adiponectin in both groups. CONCLUSIONS - Increased CD36 expression is a biomarker of PBMC activation and inflammation and may become a useful tool in cardiovascular disease risk stratification.

Original languageEnglish
Pages (from-to)2065-2067
Number of pages3
JournalDiabetes Care
Issue number9
Publication statusPublished - Sep 2010

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing


Dive into the research topics of 'Increased CD36 expression signals monocyte activation among patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this